|
55 Companies |
|
51 Products |
|
51 Products |
|
62 Mechanisms of Action |
|
0 Trials |
|
1119 News |
|
| «12...678910111213141516...1920» |
- ||| Clinical: VELPS: Validation of Early Warning Score & Lactate in Prehospital Screening (clinicaltrials.gov) - Jul 14, 2014
P=N/A, N=1000, Not yet recruiting, Sponsor: University of the West of Scotland
- esmolol / Generic mfg.
Clinical: Echocardiographic and Arterial Pressure Waveform Changes After Reducing Heart Rate With Esmolol in Septic Shock Patients (clinicaltrials.gov) - Jul 14, 2014
P=N/A, N=44, Recruiting, Sponsor: University of Roma La Sapienza
- New P1/2 trial, Surgery: Does Serum Procalcitonin Levels Predict Sepsis in Patients Undergoing Cytoreductive Surgery (clinicaltrials.gov) - Jul 14, 2014
P1/2, N=20, Recruiting, Sponsor: Eastern Regional Medical Center
- ||| Biomarker, Immune cell: Immune Failure in Critical Therapy (INFECT) Study (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=220, Not yet recruiting, Sponsor: University of Edinburgh
- Gemiglo (gemigliptin) / Sanofi, LG Chem
Clinical: Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=10, Not yet recruiting, Sponsor: Seoul National University Hospital
- Fragmin (dalteparin sodium) / Pfizer, Eisai
Trial completion: Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot (clinicaltrials.gov) - Jul 12, 2014
P2, N=76, Completed, Sponsor: University of Manitoba
Active, not recruiting --> Completed
- Trial primary completion date: Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock. (clinicaltrials.gov) - Jul 10, 2014
P2, N=60, Recruiting, Sponsor: University of Roma La Sapienza
Active, not recruiting --> Completed Trial primary completion date: Nov 2011 --> Sep 2014
- Trial primary completion date: SAPS: Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's) (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=2246, Active, not recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Nov 2011 --> Sep 2014 Trial primary completion date: Jul 2011 --> Aug 2014
- Enrollment closed, Trial primary completion date: SAPS: Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's) (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=2246, Active, not recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Jul 2011 --> Aug 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2011 --> Aug 2014
- | Trial completion: Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis (clinicaltrials.gov) - Jul 8, 2014
P3, N=115, Completed, Sponsor: Indonesia University
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2011 --> Aug 2014 Recruiting --> Completed
- Clinical: Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=1, Recruiting, Sponsor: Chinese PLA General Hospital
- | Trial completion: Efficacy and Safety of Colloids Versus Crystalloids for Fluid Resuscitation in Critically Ill Patients (clinicaltrials.gov) - Jul 1, 2014
P3, N=2857, Completed, Sponsor: University of Versailles
Recruiting --> Completed Recruiting --> Completed
- | fludrocortisone / Generic mfg., hydrocortisone / Generic mfg.
Enrollment open: APROCCHS: Activated Protein C and Corticosteroids for Human Septic Shock (clinicaltrials.gov) - Jul 1, 2014
P3, N=1280, Recruiting, Sponsor: University of Versailles
Recruiting --> Completed Suspended --> Recruiting
- Trial primary completion date: Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=1344, Completed, Sponsor: JESUS RODRIGUEZ BAÑO
Suspended --> Recruiting Trial primary completion date: Sep 2013 --> Dec 2013
- Enrollment change: Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=1344, Completed, Sponsor: JESUS RODRIGUEZ BAÑO
Trial primary completion date: Sep 2013 --> Dec 2013 N=2000 --> 1344
- Trial completion, Enrollment change, Trial primary completion date: Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=1344, Completed, Sponsor: JESUS RODRIGUEZ BAÑO
N=2000 --> 1344 Recruiting --> Completed | N=2000 --> 1344 | Trial primary completion date: Sep 2013 --> Dec 2013
- Clinical: ARDS Prediction Score in Critically Ill Patients in China (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=1, Recruiting, Sponsor: Jianfeng Xie
- Trial primary completion date: The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=16, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting --> Completed | N=2000 --> 1344 | Trial primary completion date: Sep 2013 --> Dec 2013 Trial primary completion date: Jul 2015 --> Dec 2015
- Review, Enrollment change: Outcomes of Severe Sepsis Patients in Surgical Intensive Care Units (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=762, Completed, Sponsor: National Taiwan University Hospital
Trial primary completion date: Jul 2015 --> Dec 2015 N=1100 --> 762
- Enrollment open, Trial primary completion date: The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=16, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
N=1100 --> 762 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Dec 2015
- Trial completion, Review, Enrollment change: Outcomes of Severe Sepsis Patients in Surgical Intensive Care Units (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=762, Completed, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Dec 2015 Recruiting --> Completed | N=1100 --> 762
- Trial initiation date, Surgery: Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2 (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=330, Recruiting, Sponsor: University of Michigan
Recruiting --> Completed | N=1100 --> 762 Initiation date: Mar 2014 --> Jun 2014
- Enrollment open, Trial initiation date, Surgery: Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2 (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=330, Recruiting, Sponsor: University of Michigan
Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jun 2014
- Enrollment open, Surgery: HAI: Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=13925, Recruiting, Sponsor: Dr. Donald Likosky
Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- || Vabomere (meropenem/vaborbactam) / Melinta Therap
New P3 trial: Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults (clinicaltrials.gov) - Jun 22, 2014
P3, N=150, Not yet recruiting, Sponsor: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
- Trial primary completion date: Hyper2S: Hyperoxia and Hypertonic Saline in Septic Shock (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=441, Active, not recruiting, Sponsor: University Hospital, Angers
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2015 --> Jun 2014
- Enrollment change: Hyper2S: Hyperoxia and Hypertonic Saline in Septic Shock (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=441, Active, not recruiting, Sponsor: University Hospital, Angers
Trial primary completion date: Nov 2015 --> Jun 2014 N=800 --> 441
- Enrollment closed, Enrollment change, Trial primary completion date: Hyper2S: Hyperoxia and Hypertonic Saline in Septic Shock (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=441, Active, not recruiting, Sponsor: University Hospital, Angers
N=800 --> 441 Recruiting --> Active, not recruiting | N=800 --> 441 | Trial primary completion date: Nov 2015 --> Jun 2014
- Trial primary completion date: Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=900, Recruiting, Sponsor: Fundación Pública Andaluza Progreso y Salud
Recruiting --> Active, not recruiting | N=800 --> 441 | Trial primary completion date: Nov 2015 --> Jun 2014 Trial primary completion date: Dec 2013 --> Jun 2014
- Enrollment change: Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=75, Recruiting, Sponsor: Yale University
Trial primary completion date: Dec 2013 --> Jun 2014 N=214 --> 75
- Enrollment change: High MAP in Septic Shock With Hypertension (clinicaltrials.gov) - Jun 18, 2014
P4, N=19, Completed, Sponsor: Southeast University, China
N=214 --> 75 N=24 --> 19
- Phase classification: High MAP in Septic Shock With Hypertension (clinicaltrials.gov) - Jun 18, 2014
P4, N=19, Completed, Sponsor: Southeast University, China
N=24 --> 19 Phase classification: P=N/A --> P4
- ||| Clinical: Serial Therapeutic and Antifungal Monitoring Protocol (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: T2 Biosystems
- Trial completion, Phase classification, Enrollment change: High MAP in Septic Shock With Hypertension (clinicaltrials.gov) - Jun 18, 2014
P4, N=19, Completed, Sponsor: Southeast University, China
Phase classification: P=N/A --> P4 Recruiting --> Completed | Phase classification: PN/A --> P4 | N=24 --> 19
- Biomarker: Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=130, Recruiting, Sponsor: University of Florida
- || pentoxifylline / Generic mfg.
New P3 trial: Pentoxifylline and Late Onset Sepsis in Preterm Infants (clinicaltrials.gov) - Jun 13, 2014
P3, N=120, Completed, Sponsor: Abd Elazeez Attala Shabaan
- || Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
Phase classification: Understanding the Immune Response to Meningitis Vaccines (clinicaltrials.gov) - Jun 12, 2014
P3, N=150, Completed, Sponsor: University of Oxford
Recruiting --> Completed | Phase classification: PN/A --> P4 | N=24 --> 19 Phase classification: P2 --> P3
- ||| Trial completion: Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT) (clinicaltrials.gov) - Jun 5, 2014
P=N/A, N=700, Completed, Sponsor: T2 Biosystems
Phase classification: P2 --> P3 Recruiting --> Completed
- Trial completion: THEMIS: Thermodilution - Controlled Management of Volume Therapy in Septic Shock (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=60, Completed, Sponsor: Claudia Spies
Recruiting --> Completed Recruiting --> Completed
- ||| Observational data: SEA050: An Observational Study of the Causes, Management, and Outcomes of Community-acquired Sepsis and Severe Sepsis in Southeast Asia (clinicaltrials.gov) - Jun 3, 2014
P=N/A, N=2250, Recruiting, Sponsor: University of Oxford
- |||| Trial primary completion date: EUPHRATES: Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock (clinicaltrials.gov) - Jun 2, 2014
P3, N=650, Recruiting, Sponsor: Spectral Diagnostics (US) Inc.
Recruiting --> Completed Trial primary completion date: Jan 2015 --> Jul 2016
- ||||| Enrollment change: EUPHRATES: Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock (clinicaltrials.gov) - Jun 2, 2014
P3, N=650, Recruiting, Sponsor: Spectral Diagnostics (US) Inc.
Trial primary completion date: Jan 2015 --> Jul 2016 N=360 --> 650
- Trial primary completion date: TRISS: Transfusion-requirements in Septic Shock Trial (clinicaltrials.gov) - May 26, 2014
P3, N=1000, Active, not recruiting, Sponsor: Scandinavian Critical Care Trials Group
N=360 --> 650 Trial primary completion date: Dec 2013 --> Mar 2014
- Enrollment change: A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis (clinicaltrials.gov) - May 25, 2014
P1/2, N=0, Withdrawn, Sponsor: AM-Pharma
Trial primary completion date: Dec 2013 --> Mar 2014 N=20 --> 0
- Trial primary completion date: Prevalence of CVC-associated Sepsis and Use of Blood Cultures in Berlin - Brandenburg (clinicaltrials.gov) - May 22, 2014
P=N/A, N=80, Recruiting, Sponsor: Charite University, Berlin, Germany
N=20 --> 0 Trial primary completion date: Feb 2014 --> Oct 2014
- Trial completion date: Prevalence of CVC-associated Sepsis and Use of Blood Cultures in Berlin - Brandenburg (clinicaltrials.gov) - May 22, 2014
P=N/A, N=80, Recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Feb 2014 --> Oct 2014 Trial completion date: Feb 2014 --> Oct 2014
- Trial primary completion date: FC-Rev: Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock? (clinicaltrials.gov) - May 21, 2014
P=N/A, N=145, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Trial completion date: Feb 2014 --> Oct 2014 Trial primary completion date: Mar 2016 --> May 2015
- Trial primary completion date: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - May 21, 2014
P=N/A, N=361, Recruiting, Sponsor: University of British Columbia
Trial primary completion date: Mar 2016 --> May 2015 Trial primary completion date: Sep 2013 --> Dec 2014
- Trial initiation date: FC-Rev: Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock? (clinicaltrials.gov) - May 21, 2014
P=N/A, N=145, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Trial primary completion date: Sep 2013 --> Dec 2014 Initiation date: Mar 2015 --> May 2014
- Trial completion date: FC-Rev: Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock? (clinicaltrials.gov) - May 21, 2014
P=N/A, N=145, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Initiation date: Mar 2015 --> May 2014 Trial completion date: Mar 2016 --> May 2015